Artículos por temáticas

A critical review on neurodegenerative biomarker diagnostics: where is the field heading to?

Amiri M, Afshary H, Bezaatpour A, Hatamikia S, Wei J, Boukherroub R, Szunerits S.

Anal Bioanal Chem. 2025 Oct;417(24):5435-5448. doi: 10.1007/s00216-025-06061-1. Epub 2025 Oct 7.

GAA-FGF14 Expansions and CACNA1A Variants: Phenotypic Overlap and Diagnostic Implications

Indelicato E, Fleszar Z, Pellerin D, Nachbauer W, Zuchner S, Traschütz A, Amprosi M, Schöls L, Haack TB, Brais B, Boesch S, Synofzik M.

Mov Disord. 2025 Oct;40(10):2262-2268. doi: 10.1002/mds.30328. Epub 2025 Aug 19.

Sex differences in neurological disorders: Insights from ischemic stroke, Parkinson's disease, and multiple sclerosis

Kaufhold CJ, Mani KK, Akbari Z, Sohrabji F.

Brain Behav Immun. 2025 Oct;129:335-347. doi: 10.1016/j.bbi.2025.06.026. Epub 2025 Jun 18.

Surprises From the Basal Ganglia: Stop and Go Have New Meaning

Graybiel AM.

Mov Disord. 2025 Oct;40(10):2077-2082. doi: 10.1002/mds.70008. Epub 2025 Aug 14.

Exploring spatiotemporal and kinematic gait parameters in individuals with Parkinson's disease across different motor phenotypes: A comparative study with and without dopaminergic therapy

Yu IH, Lai YR, Ting CP, Lien CY, Huang CC, Kung CF, Chiang YF, Lu CH.

Gait Posture. 2025 Oct;122:211-217. doi: 10.1016/j.gaitpost.2025.07.318. Epub 2025 Jul 19.

The emerging landscape of brain glycosylation: from molecular complexity to therapeutic potential

Seo Y, Park JE, Yu JY, Lee B, Yoon JH, An HJ.

Exp Mol Med. 2025 Oct 14. doi: 10.1038/s12276-025-01560-8. Online ahead of print.

Gut Permeability and Microbiota in Parkinson's Disease: Mechanistic Insights and Experimental Therapeutic Strategies

Liang Y, Zhao Y, Fasano A, Su CW.

Int J Mol Sci. 2025 Oct 1;26(19):9593. doi: 10.3390/ijms26199593.

Neuroprotection in Parkinson Disease

Gonzalez-Robles C, Bandmann O, Schapira AHV.

Neurol Ther. 2025 Oct;14(5):1747-1767. doi: 10.1007/s40120-025-00793-z. Epub 2025 Jul 18.

Fecal Microbiota Transplantation for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Waseem MH, Abideen ZU, Shoaib A, Rehman N, Osama M, Sajid B, Ahmad R, Fahim Z, Ansari MW, Aimen S, Cheema AH, Thada PK.

J Cent Nerv Syst Dis. 2025 Oct 14;17:11795735251388781. doi: 10.1177/11795735251388781. eCollection 2025.

Emerging Molecular Targets in Neurodegenerative Disorders: New Avenues for Therapeutic Intervention

Eroglu E, Harmanci N.

Basic Clin Pharmacol Toxicol. 2025 Oct;137(4):e70107. doi: 10.1111/bcpt.70107.

Parkinson's disease participant-led research: Towards neuroimaging-assisted deep brain stimulation programming

McAuley MD, Ionova AA, Horn A, Heming E, Onabajo CA, Solie MM, Stephenson SA, Boehnke SE.

J Parkinsons Dis. 2025 Oct 3:1877718X251381454. doi: 10.1177/1877718X251381454. Online ahead of print.

Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme (PBS) Data

Logan PA, Micalos PS, Fealy S, Bramble M, Wong A.

Aust J Rural Health. 2025 Oct;33(5):e70094. doi: 10.1111/ajr.70094.

Research trends of piezoelectric materials in neurodegenerative disease applications

Wang X, Sun Y, Han C, Meng X, Wen K, Wu J, Min P, Li K, Zhang Y.

Bioact Mater. 2025 Jun 13;52:366-392. doi: 10.1016/j.bioactmat.2025.06.022. eCollection 2025 Oct.

Exergame-Based Program and Conventional Physiotherapy Based on Core Areas of the European Guideline Similarly Improve Gait and Cognition in People with Parkinson's Disease: Randomized Clinical Trial

Nuvolini RA, Silva KGD, Freitas TB, Doná F, Torriani-Pasin C, Pompeu JE.

Games Health J. 2025 Oct;14(5):358-368. doi: 10.1089/g4h.2024.0116. Epub 2025 Mar 31.

Retraction: miR-335 targets LRRK2 and mitigates inflammation in Parkinson's disease

Frontiers Editorial Office.

Front Cell Dev Biol. 2025 Oct 6;13:1712881. doi: 10.3389/fcell.2025.1712881. eCollection 2025.